The 36 spots between Axon and Palantir are price dressed up as growth

This week's Roundtable 100 puts Axon Enterprise at rank 27 and Palantir at rank 63, a 36-spot gap in favor of the TASER-and-body-camera maker over the government's AI data platform. The ranking's stated line is that Axon has "significantly more room to grow" and that Palantir, despite its hype, is "a far weaker growth play."

That sentence is doing heavy lifting that the reported numbers do not support — and if you are deciding whether either stock belongs on your watchlist, it is the sentence worth auditing before the rank itself.

Start with the screen, then the underlying financials. On the growth question, the two companies point the opposite way from the ranking's framing. Palantir grew revenue 93% year over year in Q2 to $1.94 billion and raised its full-year 2026 guidance to 82% growth. Axon grew 35% in the same quarter to $904 million and kept its guidance around 32–34%. By the trailing record, Palantir is growing roughly two and a half times faster than Axon, not the reverse. Whatever the 36 spots are measuring, it is not who grew faster last quarter.

The six boxes behind the number

So before the gap becomes a trade, know what the number is. The Roundtable 100 is not a quantified-growth index; it is a brand-new ranking. It launched on September 1, 2026, built by Roundtable — a company that calls itself an "AI/DeFi-powered" media platform — in partnership with TheStreet.com. Each company is scored 0 to 100 on six variables — Team, Innovation, Safety, Value, Growth, and Market Dominance — and the "Power Ranking" is the average of the six, produced by a committee of tech veterans, fintech figures, and a former quant who worked for Steven Cohen. The list refreshes every Friday after market close.

That composition is the tell. Five of the six inputs are human judgment, not a reproducible formula. And only one of the six, "Growth," is about the reported financial rate. Another one, "Value," is exactly where price gets scored. So a fast-growing, extremely expensive stock and a slower-growing, cheaper stock can land 36 spots apart even when the growth box points the other way, because a full sixth of the score is carrying a valuation opinion.

The wallet, not the narrative

Here is the financial record on both, side by side, the way you would weigh them before acting.

Axon, Q2 2026: $904 million revenue, up 35%. Its software-and-services arm grew 36% to $398 million, annual recurring revenue rose 39% to $1.6 billion, and net revenue retention ran 126%. That is a healthy, compounding hardware-plus-subscription business with a real software layer and a newer counter-drone product line.

Palantir, Q2 2026: $1.94 billion revenue, up 93%. U.S. government and commercial revenue both accelerated, U.S. commercial grew 149%, and U.S.-commercial dollar retention ran 150% in the prior quarter. It is growing from a smaller base, but it is growing much faster, with customers spending more once they are inside.

Now put a price on each. Palantir carries a market cap of roughly $400 billion against about $6 billion of trailing annual revenue. Axon trades around a $39 billion market cap against roughly $3 billion of revenue. Dollar for dollar of sales, you pay roughly five times as much for a Palantir dollar as for an Axon dollar — and in exchange you get about two and a half times the latest growth rate. The Roundtable committee has quietly turned that arithmetic into a "Value" score, and that is where most of the 36 spots live.

Two readings, one decision point

None of this tells you which stock is a better buy, because valuation is a bet on the future, not a fact. The ranking is taking one side; here is the other.

The ranking's read: Axon is cheaper per unit of growth, so it has more headroom. Its 32–34% guidance is backed by a record $15.1 billion in contracted backlog and a software attach rate that keeps climbing; a slowdown is not in the current numbers.

The counter-read: Palantir's multiple is not a mistake if the growth persists. A company compounding revenue near 90% with 150% retention comfortably earns a premium that a 35% grower does not — and "cheap relative to the other one" is not the same as cheap. The reason the ranking calls Palantir a weaker play is because its price assumes the fast growth continues for years; the moment that assumption wobbles is exactly when a 47-times-sales multiple re-rates violently.

So the question that decides between them is not who sits higher on a screen. It is whether Palantir's acceleration holds — watch its dollar-retention and booked contract value, not its share price — and whether Axon's 32–34% is a floor or a ceiling. Check those against the next earnings prints.

The expiry date

This is a point-in-time opinion that refreshes every Friday, not a realized profit-and-loss statement. A rank can flutter 36 places on committee weightings alone. What retires the whole exercise is a change in the inputs beneath it: Palantir's 82% full-year guidance slipping, or Axon's guidance turning out to be the ceiling rather than the floor. When either number breaks, re-run the comparison on the fresh financials before you let this week's ranking tell you anything. The 36 spots are the headline; the two earnings reports are the evidence — and in this trade, the evidence gets re-read before the screen does.